MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. (MIST) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.9% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada.
Sector
Healthcare
Industry
Biotechnology